Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06245915 · ClinicalTrials.gov registry record · Phase 1
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
A Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Arsenal Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 9
- Study locations
NCT06245915 is a Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Arsenal Biosciences. The registered enrollment target is 37 participants, below the 529-participant average among 8 other Recurrence trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT06245915, a Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Arsenal Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Conditions Studied
Interventions
- BIOLOGICAL AB-2100
Study Locations (9)
New York
- Perlmutter Cancer Center - NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic Hospital - Phoenix
California
- City of Hope - Duarte
Florida
- Moffitt Cancer Center - Tampa
Iowa
- University of Iowa and Holden Comprehensive Cancer Center - Iowa City
Massachusetts
- Dana Farber Cancer Institue - Boston
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Univ of Utah Health - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06245915
The ClinicalTrials.gov registry entry for NCT06245915 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 529-participant average among 8 other Recurrence trials with a reported enrollment target (93% lower). The listed sponsor is Arsenal Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrence appearing as the primary indexed condition, and to 1 intervention - of which AB-2100 is the first listed.
NCT06245915 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New York, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06245915 about?
NCT06245915 is a clinical study titled "AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)". This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
What is the current status of trial NCT06245915?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2024-02-26. Estimated completion is 2028-06-30.
What conditions does trial NCT06245915 study?
This clinical trial studies the following conditions: Recurrence, Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT06245915?
The interventions under investigation include: AB-2100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06245915?
This trial is sponsored by Arsenal Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06245915 being conducted?
This trial has 9 study locations across Arizona, California, Florida, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study
RECRUITING
-
Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors
RECRUITING
-
Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System
RECRUITING
-
xDRIVE for Florida-based Cancer Patients
RECRUITING · NA
-
Cold Snare Endoscopic Mucosal Resection Trial
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.